EMA Suspends Certain Drugs Using Data from Bangalore, India-Based CRO

From DCAT Value Chain Insights (VCI)

By Regulatory News posted 07-26-2016 12:05


The European Medicines Agency (EMA) has recommended suspending a number of nationally approved medicines for which bioequivalence studies were conducted at Semler Research Center Private Ltd., a contract research organization based in Bangalore, India. The agency has also recommended that medicines currently being evaluated for authorization and which rely only on bioequivalence studies from this site should not be authorized until bioequivalence is demonstrated using alternative data. Bioequivalence studies usually form the basis for approval of generic medicines.

The EMA has published a list of medicines recommended for suspension.

The EMA’s review followed an inspection by the US Food and Drug Administration that identified several issues at Semler’s bioanalytical site, including the substitution and manipulation of subjects’ clinical samples. The World Health Organization (WHO) also raised serious concerns regarding data integrity and manipulation of study samples following its own inspections of Semler’s bioanalytical and clinical sites.

"The findings from FDA and WHO inspections call into question the quality management system in place at Semler, and thus on the reliability of the data of all bioequivalence studies, including those used to support marketing authorization applications in the EU," said the EMA in a statement. "The EMA’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the studies conducted at Semler cannot be accepted in marketing authorization applications in the EU. Thus, no medicines can be approved on the basis of these studies."

During the evaluation, alternative studies were provided for some of these medicines. These studies show bioequivalence, and therefore, the CHMP has recommended that these medicines can remain on the market.

The EMA has published a list of medicines recommended to remain on the market.

Some of the medicines that have been recommended for suspension may be of critical importance (e.g. due to lack of available alternatives) in a given EU member state. Therefore, national authorities can temporarily postpone the suspension in the interest of patients. The EMA said that member states should also decide whether recalls of the affected medicines are needed in their territories.

The CHMP’s recommendation concerning these medicines will now be sent to the European Commission for a legally binding decision valid throughout the EU.

Source: European Medicines Agency


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription